Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT(3) antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response

PJ Hesketh; SM Grunberg; J Herrstedt; Ronald de Wit; RJ Gralla; AD Carides; A Taylor; JK Evans; KJ Horgan

doi:10.1007/s00520-005-0914-4

Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT(3) antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response

PJ Hesketh, SM Grunberg, J Herrstedt, Ronald de Wit, RJ Gralla, AD Carides, A Taylor, JK Evans, KJ Horgan

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

80 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	354-360
Number of pages	7
Journal	Supportive Care in Cancer
Volume	14
Issue number	4
DOIs	https://doi.org/10.1007/s00520-005-0914-4
Publication status	Published - 2006

Access to Document

10.1007/s00520-005-0914-4

http://hdl.handle.net/1765/63508

Cite this

Hesketh, PJ., Grunberg, SM., Herrstedt, J., de Wit, R., Gralla, RJ., Carides, AD., Taylor, A., Evans, JK., & Horgan, KJ. (2006). Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT(3) antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Supportive Care in Cancer, 14(4), 354-360. https://doi.org/10.1007/s00520-005-0914-4

Hesketh, PJ ; Grunberg, SM ; Herrstedt, J ; de Wit, Ronald ; Gralla, RJ ; Carides, AD ; Taylor, A ; Evans, JK ; Horgan, KJ. / Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT(3) antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. In: Supportive Care in Cancer. 2006 ; Vol. 14, No. 4. pp. 354-360.

@article{6709c6d3d3be46d094ea72337a3a827a,

title = "Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT(3) antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response",

author = "PJ Hesketh and SM Grunberg and J Herrstedt and {de Wit}, Ronald and RJ Gralla and AD Carides and A Taylor and JK Evans and KJ Horgan",

year = "2006",

doi = "10.1007/s00520-005-0914-4",

language = "Undefined/Unknown",

volume = "14",

pages = "354--360",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

number = "4",

}

Hesketh, PJ, Grunberg, SM, Herrstedt, J, de Wit, R, Gralla, RJ, Carides, AD, Taylor, A, Evans, JK & Horgan, KJ 2006, 'Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT(3) antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response', Supportive Care in Cancer, vol. 14, no. 4, pp. 354-360. https://doi.org/10.1007/s00520-005-0914-4

Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT(3) antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. / Hesketh, PJ; Grunberg, SM; Herrstedt, J; de Wit, Ronald; Gralla, RJ; Carides, AD; Taylor, A; Evans, JK; Horgan, KJ.

In: Supportive Care in Cancer, Vol. 14, No. 4, 2006, p. 354-360.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT(3) antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response

AU - Hesketh, PJ

AU - Grunberg, SM

AU - Herrstedt, J

AU - de Wit, Ronald

AU - Gralla, RJ

AU - Carides, AD

AU - Taylor, A

AU - Evans, JK

AU - Horgan, KJ

PY - 2006

Y1 - 2006

U2 - 10.1007/s00520-005-0914-4

DO - 10.1007/s00520-005-0914-4

M3 - Article

VL - 14

SP - 354

EP - 360

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 4

ER -

Hesketh PJ, Grunberg SM, Herrstedt J, de Wit R, Gralla RJ, Carides AD et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT(3) antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Supportive Care in Cancer. 2006;14(4):354-360. https://doi.org/10.1007/s00520-005-0914-4